Cyagen Biosciences

Cyagen Biosciences is a specialized preclinical CRO that provides end-to-end research tools and services to accelerate drug discovery and development. Its core business revolves around generating high-precision genetically engineered animal models (e.g., knockout, knockin, transgenic, humanized) and custom cell lines, complemented by viral packaging and antibody discovery services. With a claimed network of 7,000 global partners and a delivery history of over 50,000 models, Cyagen positions itself as a critical enabler for preclinical research across multiple therapeutic areas, from oncology to rare diseases.

Integrated platform for genetic engineering including proprietary Turboknockout® gene editing, Cre-ESC targeting, humanized genomic ortholog (HUGO) models, custom cell line generation (iPSCs, KO/KI), viral vector (AAV, lentivirus) packaging, and AI-powered tools for AAV and antibody discovery.

Cyagen competes with large, global CROs like Charles River Laboratories and Taconic Biosciences, as well as specialized model providers like The Jackson Laboratory and genOway. Its differentiation lies in its broad, integrated service portfolio, proprietary genetic engineering technologies (e.g., HUGO, Turboknockout), and focus on supporting advanced therapeutic modalities like cell/gene therapy.